No, propafenone is contraindicated in patients with a positive stress test indicating myocardial ischemia
Propafenone should not be used in patients with ischemic heart disease, including those with positive stress tests, due to high risk of proarrhythmic effects and increased mortality. This is an absolute contraindication based on both guideline recommendations and FDA labeling.
Guideline-Based Contraindications
The ACC/AHA/HRS guidelines explicitly state that propafenone should not be used in patients with ischemic heart disease or left ventricular dysfunction 1, 2. The 2016 SVT guidelines specifically note that "flecainide and propafenone have a risk of proarrhythmia in patients with structural heart disease or ischemic heart disease and are contraindicated in these patient groups" 2.
A positive stress test indicates myocardial ischemia, which represents active coronary artery disease. This places the patient squarely in the contraindicated population.
FDA Label Warnings
The FDA labeling for propafenone reinforces this contraindication 3. Key safety data show:
- In clinical trials, 92% of patients who developed worsened ventricular tachycardia had a history of VT/VF, 71% had coronary artery disease, and 68% had prior myocardial infarction 3
- The proarrhythmic risk is particularly elevated when class IC agents are combined with myocardial ischemia 3
Mechanistic Evidence
Research demonstrates the dangerous interaction between propafenone and ischemia. A randomized, placebo-controlled study showed that during myocardial ischemia, propafenone causes a 52% increase in QTc dispersion (p=0.002), with the most pronounced effect during LAD occlusion (+74%, p=0.025) 4. This enhanced QT dispersion reflects inhomogeneous ventricular repolarization, creating substrate for life-threatening arrhythmias.
Clinical Context
The contraindication stems from the landmark CAST trial, which demonstrated increased mortality in post-MI patients with ventricular ectopy treated with class IC agents. While recent observational data 5, 6 suggest the risk may be lower in contemporary practice with stable disease, these studies:
- Are retrospective and observational
- Do not specifically address acute ischemia or positive stress tests
- Cannot override established guideline contraindications
- Should not be used to justify use in contraindicated populations
Alternative Management
For patients with positive stress tests requiring antiarrhythmic therapy:
- First priority: Address the underlying ischemia through revascularization or optimal medical management
- For rate control in atrial fibrillation: Beta-blockers, diltiazem, or verapamil are appropriate 2
- For rhythm control if needed: Amiodarone or dofetilide can be used in patients with ischemic heart disease 2, though only after ischemia is adequately managed
- Sotalol may be considered but requires careful QT monitoring 1
Critical Pitfall to Avoid
Do not rationalize propafenone use based on "stable" coronary disease or "mild" ischemia on stress testing. Any evidence of inducible ischemia represents an absolute contraindication 1, 2, 3. The increased QT dispersion during ischemia 4 creates unpredictable proarrhythmic risk that cannot be safely managed in outpatient settings.